A5043147972- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- Melanoma and MAPK Pathways
- Cancer Diagnosis and Treatment
- Cutaneous Melanoma Detection and Management
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Advanced Breast Cancer Therapies
- Radiation Dose and Imaging
- Hematological disorders and diagnostics
- Neuroendocrine Tumor Research Advances
- BRCA gene mutations in cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Vitamin C and Antioxidants Research
- Protease and Inhibitor Mechanisms
- Biological Activity of Diterpenoids and Biflavonoids
- Cancer Cells and Metastasis
- Inflammatory Biomarkers in Disease Prognosis
- Bone health and osteoporosis research
Medical Park Gaziantep Hospital
2024-2025
Gaziantep University
2021-2024
Harran University
2024
Management of melanoma has changed significantly with the discovery targeted therapies and immune checkpoint inhibitors (ICI). Our aim in study is to determine which treatment alternatives, specifically dabrafenib plus trametinib ICIs, are effective adjuvant therapy as first-line metastatic therapy. This retrospective, multicenter included 120 patients diagnosed stage IIIB-IIID receiving both between 2007 2023. Data on clinicopathologic characteristics, regimens outcomes were collected....
Background and Objectives: This study aimed to evaluate the prognostic significance of pre-treatment albumin-to-alkaline phosphatase ratio (AAPR) in early-stage colorectal cancer patients compare it with neutrophil-to-lymphocyte (NLR) platelet-to-lymphocyte (PLR) within same patient cohort. Materials Methods: retrospective included 540 who were followed up after a diagnosis whose albumin (ALB), alkaline (ALP), neutrophil, platelet, lymphocyte values measured before treatment. Results: In...
In this Turkish Oncology Group study, we aimed to evaluate the effectiveness of trastuzumab emtansine (TDM1) in adjuvant treatment early-stage human epidermal growth factor receptor-2 (HER2)-positive breast cancer with residual disease using real-life data. A total 13 centers participated study between September 2019 and October 2024. Patients HER2-positive who underwent surgery after completing neoadjuvant chemotherapy HER2-targeted therapies had invasive or axillary lymph nodes received...
Metastatic castration-resistant prostate cancer (mCRPC) remains a challenging condition to treat despite recent advancements. This retrospective study aimed assess the activity and tolerability of Lutetium-177 (Lu-177) PSMA-617 radioligand therapy (RLT) in mCRPC patients across multiple centers Turkey. The included 165 who received at least one cycle Lu-177 RLT, with majority having bone metastases undergone prior treatments. Prostate-specific antigen (PSA) levels were assessed before each...
Our aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare other treatments in patients with surgically resected stage III or IV acral melanoma. This study is a multicenter, retrospective analysis. We included 114 malignant melanoma who underwent surgery within past 10 years. analyzed effect on disease-free survival (DFS). The mean follow-up 40 months, during which 69 (59.5%) experienced recurrence. Among participants, 64 (56.1%) received...
This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines treatment in patients with metastatic neuroendocrine tumors (NETs).
Cisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, carboplatin-paclitaxel are also among the recommended regimens. In this study we aimed to evaluate efficacy of these two regimens cancer.Patients with cancer treated cisplatin-paclitaxel were retrospectively evaluated in study. The clinical demographic characteristics patients each group evaluated. Median overall survival, progression-free response rates between groups...
To investigate the prognostic and predictive value of PD-L1 expression in operated non-small cell lung cancer (NSCLC) patients to analyze its relationship with clinicopathological factors.A total 90 operable NSCLC were included this retrospective single center study. Tumor blocks stained immunohistochemically polyclonal antibody. When evaluated statistically, tumor staining percentage ≥5%, those +2 +3 membranous intensity, ≥50% H-Score considered positive. The between status features...
Aims: In this multicenter study, the authors aimed to determine real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with alectinib in terms ALK-tyrosine kinase inhibitors, regardless previous chemotherapy. The co-primary end points progression-free survival both for all treatment-naive population. secondary overall response rate, survival, rate CNS...
<title>Abstract</title> <bold>Objective:</bold>This study aimed to compare and<sup>18</sup>FDGPET/CT in patients who develop bone metastases due various cancers and investigate the prognostic significance of <sup>68</sup>FAPI-PET/CT SUVmax value for survival. <bold>Methods:</bold>Patients with underwent both <sup>68</sup>Ga-FAPI PET/CTand<sup>18</sup>FDGPET/CT within a 1-week period were included this retrospective study. The effect lesions on overall survival was analyzed....
Objective: This study aimed to analyze the predictive and prognostic value of HER2-low expression in hormone receptor (HR) positive human epidermal growth factor receptor-2 (HER2) negative metastatic breast cancer patients receiving cyclin-dependent kinase-4/6 inhibitor (CDK4/6i) therapy. Methods: retrospective included who received CDK4/6i plus endocrine therapy (ET). The pathological clinical characteristics survival times were compared analyzed. Results: Our 122 patients. There HER2-zero...
Background Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine being used as standard adjuvant treatment TNBC. We aimed to investigate the real-life data regarding efficacy capecitabine
Objective This study aimed to investigate the impact of analyzing somatic alterations using next-generation sequencing (NGS) on treatment management in patients with metastatic solid cancers and their ability access NGS recommended treatments. Methods retrospective included eligible who underwent tumor tissue. We examined clinical pathological characteristics these following results. Results A total 101 were study. The most common non-small cell lung cancer (NSCLC), colorectal, breast...
Pathologic complete response (pCR) has a strong correlation with improved survival in breast cancer.Peripheral blood values such as neutrophil to lymphocyte ratio (NLR), monocyte (LMR), platelet (PLR), systemic immuneinflammation index (SII), and pan-immune-inflammation value (PIV) have prognostic triple-negative cancer (TNBC).In this study, we aimed investigate the prediction of pCR by using peripheral prior neoadjuvant chemotherapy triple negative cancer.A total 102 patients locally...
Genetic testing for breast cancer susceptibility genes (BRCA1/2) plays a pivotal role in risk assessment and preventive interventions. However, individuals' awareness, knowledge, attitudes toward genetic can vary across different societies. This study focuses on understanding Turkish women's perceptions, BRCA1/2 testing, considering demographic factors awareness. In this cross-sectional study, 301 participants, including breast/ovarian patients their first-degree relatives, were surveyed....
To analyse the impact of COVID-19 pandemic on diagnostic method, disease stage, treatment modalities, and survival operated non-small cell lung cancer (NSCLC) patients.Descriptive study. Place Duration Study: Department Oncology, Gaziantep University Oncology Hospital, Sahinbey, Turkey, from March 2018 to 2022.Patients who were for NSCLC screened retrospectively. The demographic clinical characteristics patients, infection time analysed compared after dividing patient into prepandemic groups...
Aim: Vitamin D has a role in carcinogenesis and may have effect on recurrence. Thus, we aim to analyze the prognostic of vitamin levels at beginning follow-up together with contribution supplementation patients colorectal cancer (CRC). Materials & methods: CRC who underwent curative surgery were included. Patients' values assessed under four groups according baseline values, whether was used. Survival distributions compared for groups. Results: Patients high level after presented better...
Sarcomatoid renal cell carcinoma (sRCC) is a rare variant of (RCC) and associated with poor prognosis.We reviewed the outcomes patients from oncology centers in Turkey.Our aim to share our real-life experience contribute literature.The demographic clinical features, treatment, survival 148 sRCC were analyzed.The median age at time diagnosis was 58 years (range: 19-83 years).Most (62.8%) had clear-cell histology.Most intermediate Memorial Sloan-Kettering Cancer Center (MSKCC) risk group...
Abstract Introduction: Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that percentage tumor cells patient groups receiving crizotinib might affect outcomes. This study aimed to investigate whether had a predictive effect NSCLC who received as ALK-TKI. Materials and Methods: retrospective included advanced-stage alectinib ALK-TKI whose was determined by...
Abstract Objectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 20 mutation-positive non-small cell lung cancer (NSCLC). Materials Methods We retrospectively evaluated characteristics 125 mutated NSCLC who received erlotinib or afatinib as first line treatment between 2012 2021 from 34 oncology centres. Since insertion is associated TKI resistance, these were excluded study. Results mutations seen 60%, 16%,...